hodgkin's lymphoma

Rosenthal Discusses the Need for Standardized Care in AYA ...

OncLive - 02 Feb 2023
Rosenthal Discusses the Need for Standardized Care in AYA ... ...

Brentuximab Vedotin Plus Nivolumab/Dacarbazine/Doxorubicin ...

OncLive - 31 Jan 2023
Brentuximab Vedotin Plus Nivolumab/Dacarbazine/Doxorubicin ... ...

NICE Recommends Axicabtagene Ciloleucel for Lymphoma

OncLive - 30 Jan 2023
NICE Recommends Axicabtagene Ciloleucel for Lymphoma ...

Pembrolizumab Following ASCT Generates Promising PFS in T-cell ...

OncLive - 23 Jan 2023
Pembrolizumab Following ASCT Generates Promising PFS in T-cell ... ...

ASH 2022: Bispecific Antibodies

AJMC.com Managed Markets Network - 04 Feb 2023
ASH 2022: Bispecific Antibodies ...

U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non ...

Investors | Eli Lilly and Company - 27 Jan 2023
U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non ... ...

Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ...

OncLive - 16 Jan 2023
Axi-cel Maintains PFS and ORR Benefit in 3-Year Follow-Up of ... ...

World Cancer Day: How a Sharjah girl, 11, overcame an elusive cancer

Gulf News - 04 Feb 2023
World Cancer Day: How a Sharjah girl, 11, overcame an elusive cancer ...

Researchers Form Novel Database of Leukemia Transcriptome ...

AJMC.com Managed Markets Network - 20 Jan 2023
Researchers Form Novel Database of Leukemia Transcriptome ... ...

Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in ...

OncLive - 28 Jan 2023
Magrolimab Plus Rituximab/Chemo Elicits Deep Responses in ... ...

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy ...

Merck - 25 Jan 2023
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy ... ...

Review of Hematology-Oncology Emergencies for Internal Medicine ...

Cureus - 09 Jan 2023
Review of Hematology-Oncology Emergencies for Internal Medicine ... ...

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial ...

Bristol-Myers Squibb - 02 Feb 2023
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial ... ...

Why do the greatest athletes seem to have the most reluctant ...

Daily Herald - 04 Feb 2023
Why do the greatest athletes seem to have the most reluctant ... ...

Overall Survival with Brentuximab Vedotin in Stage III or IV ...

nejm.org - 28 Jul 2022
Overall Survival with Brentuximab Vedotin in Stage III or IV ... ...

Rep. Jamie Raskin has diffuse large B-cell lymphoma. Here's what ...

The Washington Post - 29 Dec 2022
Rep. Jamie Raskin has diffuse large B-cell lymphoma. Here's what ... ...

Novel Targeted Immunotherapies Strengthen Frontline Treatment ...

OncLive - 15 Dec 2022
Novel Targeted Immunotherapies Strengthen Frontline Treatment ... ...

Breast Lymphoma: Symptoms, Causes, Treatment, and Outlook

Healthline - 15 Sep 2022
Breast Lymphoma: Symptoms, Causes, Treatment, and Outlook ...

Interim FDG-PET/CT for therapy monitoring and prognostication in ...

Nature.com - 21 Oct 2022
Interim FDG-PET/CT for therapy monitoring and prognostication in ... ...